IN2015DN03133A - - Google Patents
Info
- Publication number
- IN2015DN03133A IN2015DN03133A IN3133DEN2015A IN2015DN03133A IN 2015DN03133 A IN2015DN03133 A IN 2015DN03133A IN 3133DEN2015 A IN3133DEN2015 A IN 3133DEN2015A IN 2015DN03133 A IN2015DN03133 A IN 2015DN03133A
- Authority
- IN
- India
- Prior art keywords
- compounds
- pyridazinone
- disclosure
- thyroid hormone
- allow
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 5
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- -1 pyridazinone compound Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000005495 thyroid hormone Substances 0.000 abstract 1
- 229940036555 thyroid hormone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large- scale preparation of pyridazinone compounds having high purity. In some embodiments , preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRP mutation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702137P | 2012-09-17 | 2012-09-17 | |
| US201361790432P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/060177 WO2014043706A1 (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03133A true IN2015DN03133A (en) | 2015-10-02 |
Family
ID=50278769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3133DEN2015 IN2015DN03133A (en) | 2012-09-17 | 2013-09-17 |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US9266861B2 (en) |
| EP (3) | EP4023641B1 (en) |
| JP (7) | JP6616688B2 (en) |
| KR (4) | KR102138750B1 (en) |
| CN (2) | CN105008335B (en) |
| AR (1) | AR092872A1 (en) |
| AU (1) | AU2013315017C1 (en) |
| BR (2) | BR112015005891A2 (en) |
| CA (3) | CA3090070C (en) |
| DK (2) | DK3689853T3 (en) |
| ES (2) | ES2907926T3 (en) |
| HK (1) | HK1212682A1 (en) |
| IL (5) | IL237628B (en) |
| IN (1) | IN2015DN03133A (en) |
| MX (2) | MX364661B (en) |
| MY (1) | MY170520A (en) |
| NZ (2) | NZ705827A (en) |
| RU (2) | RU2018128393A (en) |
| SG (3) | SG10202006058QA (en) |
| TW (4) | TWI755628B (en) |
| WO (1) | WO2014043706A1 (en) |
| ZA (1) | ZA201501795B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018128393A (en) * | 2012-09-17 | 2019-03-14 | Мадригал Фармасьютикалз, Инк. | METHOD FOR SYNTHESIS OF ANALOGUES OF THYROID HORMONES AND THEIR POLYMORPHES |
| IL266054B2 (en) | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| US11485729B2 (en) | 2018-01-23 | 2022-11-01 | Shenzhen Targetrx, Inc. | Substituted pyridazinone compound |
| WO2019240938A1 (en) | 2018-06-12 | 2019-12-19 | Fronthera U.S. Pharmaceuticals Llc | Thyroid hormone receptor agonists and uses thereof |
| WO2019242766A1 (en) * | 2018-06-22 | 2019-12-26 | 成都海创药业有限公司 | Deuterated mgl-3196 compound and use thereof |
| TW202019914A (en) * | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)- 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
| WO2020073974A1 (en) * | 2018-10-12 | 2020-04-16 | Inventisbio Shanghai Ltd. | Thyroid hormone receptor agonists |
| JP7445996B2 (en) * | 2019-02-21 | 2024-03-08 | ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド | Novel compounds and their use as thyroid hormone receptor agonists |
| JP2022532706A (en) * | 2019-05-08 | 2022-07-19 | アリゴス セラピューティクス，インコーポレーテッド | THR-β regulator and its usage |
| CN111909137B (en) * | 2019-05-10 | 2023-05-30 | 深圳微芯生物科技股份有限公司 | Pyridazinone derivative and application thereof |
| WO2020239076A1 (en) * | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | Pyridazinone derivatives as thyroxine receptor-β agonists and application thereof |
| CN112442013B (en) * | 2019-09-04 | 2022-07-26 | 广东东阳光药业有限公司 | Compound serving as thyroid hormone beta receptor agonist and application thereof |
| WO2021063367A1 (en) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | Resmetirom crystal form and preparation method therefor and use thereof |
| CN112707892A (en) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof |
| EP4083024A4 (en) * | 2019-11-26 | 2023-11-01 | KPC Pharmaceuticals, Inc. | 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof |
| WO2021121210A1 (en) * | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | Fused-ring derivative, and preparation method therefor and medical use thereof |
| WO2021129465A1 (en) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | Resmetirom crystal, preparation method for same, and uses thereof |
| WO2022041026A1 (en) * | 2020-08-27 | 2022-03-03 | InventisBio Co., Ltd. | Pyridazinone compounds |
| CN116171275A (en) * | 2020-09-10 | 2023-05-26 | 苏州科睿思制药有限公司 | Crystal form of Resmetirom and preparation method and application thereof |
| WO2022086894A1 (en) | 2020-10-19 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| TW202245775A (en) | 2021-02-01 | 2022-12-01 | 美商瑪德瑞高製藥公司 | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders |
| CN114907327A (en) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Crystal form of Resmetirom and preparation method and application thereof |
| CN115073429A (en) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | Salt form and crystal form of 1,2, 4-triazine-3, 5-diketone compound and preparation method thereof |
| CA3233319A1 (en) | 2021-09-27 | 2023-03-30 | Rebecca Taub | Resmetirom for reducing liver volume |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) * | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| EP1587830B1 (en) | 2003-01-28 | 2009-07-08 | Academisch Ziekenhuis Leiden | Peptide inhibitors of toxins derived from ll-37 |
| WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| ITRM20030363A1 (en) | 2003-07-24 | 2005-01-25 | Fernando Goglia | COMPOSITIONS INCLUDING 3THIODOTYRONIN AND PHARMACEUTICAL USE OF THEM. |
| US20050287667A1 (en) * | 2004-06-01 | 2005-12-29 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| US7807647B2 (en) * | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| EP1812408B1 (en) | 2004-11-02 | 2013-10-09 | Northwestern University | Pyridazine compounds, compositions and methods |
| DE602006016821D1 (en) | 2005-07-21 | 2010-10-21 | Hoffmann La Roche | PYRIDAZINE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS |
| EA019084B1 (en) | 2007-06-06 | 2014-01-30 | Торрент Фармасьютикалс Лтд. | Novel thyroid compounds for treating diseases associated with metabolism |
| US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| RU2018128393A (en) | 2012-09-17 | 2019-03-14 | Мадригал Фармасьютикалз, Инк. | METHOD FOR SYNTHESIS OF ANALOGUES OF THYROID HORMONES AND THEIR POLYMORPHES |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| JP6553067B2 (en) | 2014-02-14 | 2019-07-31 | センプラ ファーマシューティカルズ，インコーポレイテッド | Compositions and methods for treating diabetes and liver disease |
| IL266054B2 (en) | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| WO2019240938A1 (en) | 2018-06-12 | 2019-12-19 | Fronthera U.S. Pharmaceuticals Llc | Thyroid hormone receptor agonists and uses thereof |
| TW202019914A (en) | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)- 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
| WO2020073974A1 (en) | 2018-10-12 | 2020-04-16 | Inventisbio Shanghai Ltd. | Thyroid hormone receptor agonists |
| CN111320609A (en) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | THR β receptor agonist compound and preparation method and application thereof |
-
2013
- 2013-09-17 RU RU2018128393A patent/RU2018128393A/en unknown
- 2013-09-17 CN CN201380059943.5A patent/CN105008335B/en active Active
- 2013-09-17 EP EP21209827.1A patent/EP4023641B1/en active Active
- 2013-09-17 NZ NZ705827A patent/NZ705827A/en unknown
- 2013-09-17 WO PCT/US2013/060177 patent/WO2014043706A1/en active Application Filing
- 2013-09-17 KR KR1020187034908A patent/KR102138750B1/en active IP Right Grant
- 2013-09-17 RU RU2015114327A patent/RU2668960C2/en active
- 2013-09-17 NZ NZ73964513A patent/NZ739645A/en unknown
- 2013-09-17 CA CA3090070A patent/CA3090070C/en active Active
- 2013-09-17 EP EP13837402.0A patent/EP2895466B1/en active Active
- 2013-09-17 MY MYPI2015000591A patent/MY170520A/en unknown
- 2013-09-17 AU AU2013315017A patent/AU2013315017C1/en active Active
- 2013-09-17 TW TW108132827A patent/TWI755628B/en active
- 2013-09-17 CA CA2884481A patent/CA2884481C/en active Active
- 2013-09-17 KR KR1020217019940A patent/KR102363776B1/en active IP Right Grant
- 2013-09-17 BR BR112015005891A patent/BR112015005891A2/en not_active Application Discontinuation
- 2013-09-17 BR BR122021024202-0A patent/BR122021024202B1/en active IP Right Grant
- 2013-09-17 KR KR1020157009807A patent/KR101966490B1/en active IP Right Grant
- 2013-09-17 TW TW110117935A patent/TWI804870B/en active
- 2013-09-17 DK DK20157696.4T patent/DK3689853T3/en active
- 2013-09-17 EP EP20157696.4A patent/EP3689853B1/en active Active
- 2013-09-17 DK DK13837402.0T patent/DK2895466T3/en active
- 2013-09-17 CA CA3111317A patent/CA3111317C/en active Active
- 2013-09-17 SG SG10202006058QA patent/SG10202006058QA/en unknown
- 2013-09-17 ES ES20157696T patent/ES2907926T3/en active Active
- 2013-09-17 TW TW107137798A patent/TWI681957B/en active
- 2013-09-17 IN IN3133DEN2015 patent/IN2015DN03133A/en unknown
- 2013-09-17 ES ES13837402T patent/ES2795450T3/en active Active
- 2013-09-17 MX MX2015003418A patent/MX364661B/en active IP Right Grant
- 2013-09-17 AR ARP130103332A patent/AR092872A1/en unknown
- 2013-09-17 KR KR1020207005528A patent/KR20200023528A/en not_active IP Right Cessation
- 2013-09-17 JP JP2015532148A patent/JP6616688B2/en active Active
- 2013-09-17 TW TW102133687A patent/TWI652260B/en active
- 2013-09-17 CN CN201810077707.0A patent/CN108101851A/en active Pending
- 2013-09-17 SG SG10201705984XA patent/SG10201705984XA/en unknown
- 2013-09-17 SG SG11201501907YA patent/SG11201501907YA/en unknown
-
2015
- 2015-03-09 IL IL237628A patent/IL237628B/en active IP Right Grant
- 2015-03-16 ZA ZA2015/01795A patent/ZA201501795B/en unknown
- 2015-03-17 US US14/660,720 patent/US9266861B2/en active Active
- 2015-03-17 MX MX2018014924A patent/MX2018014924A/en unknown
-
2016
- 2016-01-18 HK HK16100496.1A patent/HK1212682A1/en unknown
- 2016-02-17 US US15/046,213 patent/US9968612B2/en active Active
-
2017
- 2017-12-26 JP JP2017249107A patent/JP6532931B2/en active Active
-
2018
- 2018-04-10 US US15/949,389 patent/US10376517B2/en active Active
- 2018-05-27 IL IL259610A patent/IL259610B/en active IP Right Grant
- 2018-11-20 JP JP2018217045A patent/JP6765408B2/en active Active
-
2019
- 2019-02-25 IL IL265030A patent/IL265030B/en active IP Right Grant
- 2019-07-01 US US16/458,546 patent/US10894050B2/en active Active
- 2019-08-27 JP JP2019154299A patent/JP6899413B2/en active Active
-
2020
- 2020-02-10 JP JP2020020343A patent/JP7038745B2/en active Active
- 2020-06-15 IL IL275393A patent/IL275393B/en unknown
- 2020-12-11 US US17/118,706 patent/US11564926B2/en active Active
-
2021
- 2021-11-15 IL IL288133A patent/IL288133A/en unknown
-
2022
- 2022-03-07 JP JP2022034154A patent/JP7436542B2/en active Active
- 2022-12-15 US US18/066,677 patent/US20230210856A1/en active Pending
-
2023
- 2023-12-22 US US18/393,818 patent/US20240148742A1/en active Pending
- 2023-12-22 US US18/393,813 patent/US11986481B2/en active Active
-
2024
- 2024-02-07 JP JP2024016915A patent/JP2024056793A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03133A (en) | ||
| JOP20210065A1 (en) | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | |
| PH12015502839A1 (en) | Antiviral compounds | |
| IN2014MN02459A (en) | ||
| EP2681204A4 (en) | Synthesis of intermediate for treprostinil production | |
| MY178759A (en) | Method for preparing trichlorosilane | |
| WO2012031045A3 (en) | Phosphonate ester derivatives and methods of synthesis thereof | |
| UA116825C2 (en) | Morphic forms of hexadecyloxypropyl-phosphonate esters | |
| EP3760637A3 (en) | Stable solid forms of regadenoson | |
| IN2014MN00976A (en) | ||
| GB201210256D0 (en) | Improved butanol recovery process | |
| PH12015500061A1 (en) | Method for preparing substituted triazolopyridines | |
| BR112012031086A2 (en) | agomelatine intermediates and method of preparation thereof | |
| PH12014502495A1 (en) | Method for producing refined glycerin alkyl ether | |
| TN2014000329A1 (en) | Method for preparing compound by novel michael addition reaction using water or various acids as additive | |
| IN2014DN03245A (en) | ||
| MX368061B (en) | Radiolabelling process. | |
| PH12015501840A1 (en) | Production method of pyridazinone compounds | |
| IN2012DE00267A (en) | ||
| GB201103455D0 (en) | Radiofluorination method | |
| IN2013MU03467A (en) | ||
| IN2011CH03419A (en) | ||
| IN2013DE00241A (en) |